MedTrace Logo

Ticagrelor for the Comatose

NCT02175875 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 47

Last updated 2016-04-07

No results posted yet for this study

Summary

The study will investigate the effect of the oral antiplatelet agent ticagrelor (Brilique) when it is administrated through a nasogastric tube in comatose patients. The platelet function can be determined by various platelet function tests (PFT), Multiplate and VerifyNow . As control, the reference intervals from the literature are used. Futhermore, plasma concentrations of the active metabolite will be determined at aeveral timepoints after first intake of a bolus dose.

Conditions

  • Comatose

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • Lene Holmvang

    lead OTHER

Principal Investigators

  • Lene Holmvang, MD, PHD · Rigshospitalet, Denmark

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-09-30
Primary Completion
2015-09-30
Completion
2015-10-31

Countries

  • Denmark

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02175875 on ClinicalTrials.gov